# [Corrected]
**AGENCY:**
Food and Drug Administration, HHS.
**ACTION:**
Final rule, correction.
**SUMMARY:**
The Food and Drug Administration (FDA) is correcting a final rule that appeared in the *Federal Register* of May 3, 2012. (77 FR 26162). The final rule provides manufacturers of biological products greater flexibility, as appropriate, and encourages use of the most appropriate and state-of-the-art test methods for assuring the safety of biological products. The rule was published with an inaccurate citation in the codified section of the rule. This notice corrects that error.
**DATES:**
Effective June 4, 2012.
**FOR FURTHER INFORMATION CONTACT:**
Paul E. Levine, Jr., Center for Biologics Evaluation and Research (HFM-17), Food and Drug Administration, 1401 Rockville Pike, Suite 200N, Rockville, MD 20852-1448, 301-827-6210.
**SUPPLEMENTARY INFORMATION:**
In FR Doc. 2012-10649, appearing on page 26162 in the *Federal Register* of Thursday, May 3, 2012, the following correction is made:
**21 CFR Part 680**
§ 680.3
1. On page 26175, in the second column, in Part 680 Additional Standards for Miscellaneous Products, in § 680.3 Tests, paragraph (c), in line 4, “§ 601.12” is corrected to read “§ 610.12”.
Dated: May 18, 2012.
Leslie Kux,
Assistant Commissioner for Policy.